AI medical unicorn Hangzhou Diagens Biotechnology Co., Ltd. makes a second attempt to list on the Hong Kong Stock Exchange: backed by the world's first medical imaging large model, with a 30.6% market share ranking first

The Hong Kong Stock Exchange disclosed on January 6, 2026 that HangzhouHangzhou Diagens Biotechnology Co., Ltd.technology Co., Ltd. has once again submitted an application for listing on the main board, with Huatai International as the sole sponsor.

Hangzhou Diagens Biotechnology Co., Ltd.'s core competitiveness lies in its world-leading technical barriers. The company's independently developed iMedImageTM medical imaging large model is claimed to be the general model with the largest parameter scale in the world, supporting 19 imaging modalities and covering more than 90% of clinical scenarios.

Relying on this technical base,Hangzhou Diagens Biotechnology Co., Ltd. holds a 30.6% share in China's chromosome karyotype analysis market, firmly ranking first in the industry. At present, the company has built a matrix of 15 major products, covering AI analysis systems, intelligent equipment, reagents and consumables, and large model services, forming a complete ecosystem.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.